Active constituents: The liposterolic (fat-soluble) extract of
saw palmetto provides concentrated amounts of free fatty acids and sterols. One study with a
saw palmetto extract suggests that it reduces the amount of dihydrotestosterone (DHT) (an
active form of testosterone) binding in the part of the prostate surrounding the urethra (the
tube carrying urine from the bladder).1 Test tube studies also suggest that saw
palmetto weakly inhibits the action of 5-alpha-reductase, the enzyme responsible for
converting testosterone to DHT.2 In test tubes, saw palmetto also inhibits the
actions of growth factors and inflammatory substances that may contribute to benign prostatic hyperplasia (BPH). Contrary to some opinions, saw
palmetto does not have an estrogen-like effect in men’s bodies.
Over the last decade, double-blind clinical trials have proven that 320 mg per day of the
liposterolic extract of saw palmetto berries is a safe and effective treatment for the
symptoms of BPH. A recent review of studies, published in the
Journal of the American Medical Association, concluded that saw palmetto extract was
as effective as finasteride (Proscar®) in the
treatment of BPH.3 The clinical effectiveness of saw palmetto has been shown in
trials lasting six months to three years.
A three-year trial in Germany found that taking 160 mg of saw palmetto extract twice daily
reduced nighttime urination in 73% of patients and improved urinary flow rates
significantly.4 In a double-blind trial, 160 mg of saw palmetto extract taken twice
daily was found to treat BPH as effectively as finasteride (Proscar) without side effects,
such as loss of libido.5
Saw palmetto extract has also been combined with a nettle
root extract to successfully treat BPH. One trial using a combination of saw palmetto extract
(320 mg per day) and nettle root extract (240 mg per day) showed positive actions on symptoms
of BPH (e.g. improved urine flow, decreased nighttime urination, etc.) over a one-year
treatment period.6 Another study compared the same combination to finasteride for
one year with positive results.7
References:
1. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term
treatment with Serenoa repens (Permixon®) on the concentrations and regional distribution
of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate
1998;37:77–83.
2. Strauch G, Perles P, Vergult G, et al. Comparison of finasteride
(Proscar®) and Serenoa repens (Permixon®) in the inhibition of 5-alpha
reductase in healthy male volunteers. Eur Urol 1994;26:247–52.
3. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment
of benign prostatic hyperplasia. JAMA 1998;280:160–9.
4. Bach D, Ebeling L. Long-term drug treatment of benign prostatic
hyperplasia—results of a prospective 3-year multicenter study using Sabal extract IDS
89. Phytomedicine 1996;3:105–11.
5. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy
(Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A
randomized international study of 1,098 patients. Prostate 1996;29:231–40.
6. Metzker H, Kieser M, Hölscher U. Efficacy of a combined
Sabal-Urtica preparation in the treatment of benign prostatic hyperplasia (BPH).Urologe
[B] 1996;36:292–300.
7. Sökeland J, Albrecht J. A combination of Sabal and Urtica
extracts versus finasteride in BPH (stage I and II according to Alken): a comparison of
therapeutic efficacy in a one-year double-blind study. Urologe [A]
1997;36:327–33.
8. Brown DJ. Herbal Prescriptions for Better Health. Rocklin,
CA: Prima Publications, 1996, 167–72.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). The Complete
Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative
Medicine Communications, 1998, 201.
10. Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage
associated with the use of extract of Saw Palmetto herb: a case report and review of
literature. J Intern Med 2001;250:167–9.
11. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy
(Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A
randomized international study of 1,098 patients. Prostate 1996;29:231–40.
12. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a
5alpha-reductase types I and II inhibitor—new evidence in a coculture model of BPH.
Prostate 1999;40:232–41.
Copyright © 2002 Healthnotes, Inc. All rights reserved.
www.healthnotes.com
Learn more about Healthnotes, the company.
Learn more about the authors of Healthnotes.
The information presented in Healthnotes is for informational
purposes only. It is based on scientific studies (human, animal, or in vitro),
clinical experience, or traditional usage as cited in each article. The results reported may
not necessarily occur in all individuals. For many of the conditions discussed, treatment with
prescription or over-the-counter medication is also available. Consult your doctor,
practitioner, and/or pharmacist for any health problem and before using any supplements or
before making any changes in prescribed medications. Information expires December 2003.